SB229, the Drug-price Transparency for Consumers Act of 2025, would require certain direct-to-consumer advertisements for prescription drugs and biological products to include pricing information. Specifically, for drugs and biologics that are covered under Medicare or Medicaid and already subject to federal ad disclosures about side effects, contraindications, and effectiveness, the bill directs the Secretary of Health and Human Services to require a clear disclosure of the wholesale acquisition cost (WAC) for a 30-day supply or typical course of treatment. The bill exempts products with a WAC below $35 for the relevant supply or course of treatment.
The legislation also requires HHS to issue implementing regulations within one year of enactment, including standards for how the price must be presented in visual and audio advertising and how quickly ads must be updated when prices change. It authorizes civil money penalties of up to $100,000 per violation for manufacturers or their agents that fail to comply, and it allows the Secretary to use public reporting information to help enforce the requirement.
Impact
The bill would amend title XI of the Social Security Act by adding a new section that expands federal oversight of prescription drug advertising. It would not directly set drug prices, but it would require manufacturers to disclose WAC in qualifying direct-to-consumer ads, affecting pharmaceutical and biologic advertisers, HHS rulemaking, and enforcement practices. The measure is aimed at consumers, insurers, and federal health programs by increasing price transparency and potentially influencing prescribing and purchasing decisions, especially for Medicare and Medicaid beneficiaries.
Sentiment
The bill appears to have generally favorable bipartisan support based on its sponsors, which include senators from both parties, and there is no recorded vote or committee opposition in the provided materials. The findings and sense of Congress frame the measure as a consumer-protection and cost-transparency proposal intended to help patients make informed decisions and reduce wasteful spending. Overall, the tone around the bill is supportive of greater transparency in drug advertising and more informed consumer choice.
Contention
The main point of contention is likely to be whether requiring list-price disclosure in advertisements meaningfully helps consumers or instead creates compliance burdens and may oversimplify what patients actually pay. The bill itself acknowledges that consumers may pay different amounts depending on insurance coverage, which highlights a possible criticism that WAC is not the same as out-of-pocket cost. Another likely area of debate is whether federal regulation of drug advertising should be expanded in this way and whether the $35 exemption and $100,000 penalty structure are appropriately calibrated.